Emitents | Grindeks, AS (5299006DWR32NKWM1O86) |
Veids | Finanšu pārskati |
Valoda | EN |
Statuss | Publicēts |
Versija | |
Datums | 2017-05-29 16:29:13 |
Versijas komentārs | |
Teksts |
The turnover and net profit of “Grindeks” to rise sharply in the first quarter of 2017
Today, on 29 May, the JSC “Grindeks” submitted the non-audited
consolidated financial statements for the first three months of
2017 to “Nasdaq Riga”. Non-audited financial results indicate that
the Group’s turnover in the first quarter of 2017 was 31.9 million
euro and has increased by 11.1 million euro or 53% in comparison to
the first quarter of 2016. In the first quarter of 2017, the
Group’s net profit, attributable to shareholders of the parent
company, was 4.51 million euro and has increased by 4.46 million
euro or 89 times compared to the first quarter of 2016. Gross
profit margin in the first quarter of 2017 was 60%, while net
profit margin was 14%. In the first quarter of 2017, the Group’s
production was exported to 52 countries worldwide, a total of 29.7
million euro which is by 11 million euro or 59% more than in the
first quarter of 2016.
Sales volume of the final dosage forms of “Grindeks” in the first
quarter of 2017 was 29.6 million euro and has increased by 10.6
million euro or 56% in comparison to the first quarter of 2016. In
the first quarter of 2017, the sales amount in Russia, other CIS
countries and Georgia reached 20.5 million euro, which is by 10.5
million euro or twice as much than in the first quarter of 2016. In
comparison to the first quarter of 2016, in the first quarter of
2017 the biggest increase in sales volume has been reached in
Russia (3.4 times), Tajikistan (2.6 times), Azerbaijan (2.4 times),
Ukraine (52%) and Kazakhstan (42%).
The sales volume in the Baltic States and other countries in the
first quarter of 2017 reached 9.1 million euro which is by 0.2
million euro or 2% more than in the first quarter of 2016. The
sales volume in Kosovo compared with the first quarter of 2016, has
increased by 3.5 times, in France by 2.7 times, in Hungary by 45%,
Lithuania by 31% and Vietnam by 19%. In the first quarter of 2017,
the sales volume in Latvia reached 1.6 million euro and has
increased by 0.04 million euro or 2% in comparison with the first
quarter of 2016.
In the first quarter of 2017,
sales of the active pharmaceutical ingredients reached 1.9 million
euro, which is by 0.4 million euro or 30% more than in the first
quarter of 2016. During this reporting period “Grindeks” mainly
exported its active pharmaceutical ingredients to the EU countries,
U.S., Australia and Japan. The most required active pharmaceutical
ingredients of “Grindeks” in the first quarter of 2017 were
ftorafur, xylazine, oxytocin, zopiclone, pimobendan and
detomidine.
The Chairman of the Board of JSC “Grindeks” Juris Bundulis: “The
net profit and turnover reached in the first quarter of 2017 shows
sharp and dynamic increase. The most remarkable increase was
reached in Russia and other CIS countries which complies with the
Group’s overall action plan and the goal set to regain its position
in these significant markets. The pharmaceutical industry is
sustainable and multifaceted business of strong competition – we
are pleased with our achievements, nevertheless, not for a moment
we refrain from using advantages and knowledge of “Grindeks”.
" About “Grindeks” “Grindeks” is an international, vertically integrated pharmaceutical company. Main fields of action are research, development, manufacturing and sales of original products, generics and active pharmaceutical ingredients. The Group of “Grindeks” consists of five subsidiary companies in Latvia, Estonia, Russia and Slovakia as well as representative offices in 12 countries. “Grindeks” specializes in the heart and cardiovascular, CNS and anti-cancer medication therapeutic groups. A range of products covers a successful combination of original products and generics, with the original products Mildronate® and Ftorafur®. Currently “Grindeks” produces 23 active pharmaceutical ingredients. Products of the company are exported to 71 countries and its export comprises 91% of the total turnover. The key markets include the EU countries, Russia and other CIS countries, the U.S., Canada, Japan and Vietnam. To increase production capacity and develop infrastructure, the company has accomplished many significant investment projects, investing more than 90 million euros over the last 15 years
Further
information: |
Pielikumi |